Assessing endoscopic remission in small bowel Crohn's disease: Are markers enough?
Authors:
Open Access
- 16 April 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Endoscopy
- Vol. 17 (4) , 106083
Abstract
Mucosal healing in Crohn’s disease (CD) has been established as a crucial target of treatment, leading to long term remission and decrease in complication rates. Endoscopy still serves as the gold standard for assessment, particularly in the small bowel where balloon or capsule enteroscopy is frequently needed. However, these modalities are often unavailable, expensive, and invasive, posing risks to patients. Consequently, the identification of accessible and reliable biomarkers, especially in small intestinal CD, remains a challenge. The study by Ohno et al , published in this issue, further illuminates this field. It confirms the potential role of fecal biomarker leucine-rich α2 glycoprotein (LRG) and validates findings from previous smaller trials. Comparing to other markers LRG showed a much higher predictive value for mucosal healing of the small bowel, making it a useful option for small intestinal CD follow up. In this editorial, we explore the optimal marker of inflammation or mucosal healing in CD, particularly in the small bowel. We provide an overview of available conventional biomarkers and introduce several novel biomarkers, including an update on emerging technologies and innovations.Keywords
This publication has 68 references indexed in Scilit:
- Fecal miR‐223 is a noninvasive biomarker for estimating Crohn's disease activityImmunity, Inflammation and Disease, 2023
- Performance of Machine Learning Algorithms for Predicting Disease Activity in Inflammatory Bowel DiseaseInflammation, 2023
- Belimumab: A Review in Systemic Lupus ErythematosusDrugs, 2018
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studiesThe Lancet, 2017
- Biomarkers—A General ReviewCurrent Protocols in Pharmacology, 2017
- B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2016
- Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitisInflammatory Bowel Diseases, 2012
- Evaluation of Fecal Myeloperoxidase as a Biomarker of Disease Activity and Severity in Ulcerative ColitisDigestive Diseases and Sciences, 2012
- Laboratory Tests in the Diagnosis and Follow-Up of Pediatric Rheumatic Diseases: An UpdateSeminars in Arthritis and Rheumatism, 2010
- Crohnʼs disease activity assessed by fecal calprotectin and lactoferrin: Correlation with Crohnʼs disease activity index and endoscopic findingsInflammatory Bowel Diseases, 2008